Dr. Lalani on a Study of Neutrophil-Lymphocyte Ratio in RCC

Aly-Khan Lalani, MD
Published: Tuesday, Oct 10, 2017



Aly-Khan Lalani, MD, genitourinary oncology fellow, Dana-Farber Cancer Institute, discusses the results of a study investigating neutrophil-lymphocyte ratio (NLR) in patients with renal cell carcinoma (RCC).

At the 6-week mark, higher NLR was associated with worse objective response rates (ORR) as well as shorter progression-free survival (PFS), and overall survival (OS) compared with those with lower NLR, according to Lalani.

Patients who had a decrease in NLR by 25% or more from baseline to 6 weeks had more favorable outcomes in terms of PFS and OS compared with patients who had an increase of 25% or more, states Lalani.
 


Aly-Khan Lalani, MD, genitourinary oncology fellow, Dana-Farber Cancer Institute, discusses the results of a study investigating neutrophil-lymphocyte ratio (NLR) in patients with renal cell carcinoma (RCC).

At the 6-week mark, higher NLR was associated with worse objective response rates (ORR) as well as shorter progression-free survival (PFS), and overall survival (OS) compared with those with lower NLR, according to Lalani.

Patients who had a decrease in NLR by 25% or more from baseline to 6 weeks had more favorable outcomes in terms of PFS and OS compared with patients who had an increase of 25% or more, states Lalani.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x